6Foged C,Nielsen HM,Frokjaer S.Liposomes for phospholipase A2 triggered siRNA release:preparation and in vitro test.Int J Pharm,2007,331(2):160-166.
7Vasir JK,Labhasetwar V.Targeted drug delivery in cancer therapy.Technol Cancer Res Treat,2005,4(4):363-374.
8Van Vlerken LE,Duan Z,Little SR,et al.Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.Mol Pharm,2008,5(4):516-526.
9Onyüksel H,Jeon E,Rubinstein I.Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells.Cancer Lett,2009,274(2):327-330.
10Shuhendler AJ,Cheung RY,Manias J,et al.A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anticancer synergy in multidrug resistant human breast cancer cells.Breast Cancer Res Treat,2010,119(2):255-269.
5Mitra S,Gaur U,Ghosh PC,et al.Tumor targeted delivery of encapsulated dextran-doxorbicin conjugate using chitosan nanoparticles as carrier[J].J Control Release,2001,74(1-3):317.
6Jorg K.Nanoparticulate systems for brain delivery of drugs[J].Advanced Drug Delivery Reviews,2001,47:65.
7Unger EC,Thomas P,William C,et al.Therapeutic applications of lipid-coated microbubbles[J].Advanced Drug Delivery Reviews,2004,56(9):1291.
8Cleland JL.Protein delivery from biodegradable microspheres[J].Pharm Biotechnol,1997,10:1.
9Gao J,Niklasonl,Zhao XM,et al.Surface modification of polyanhydride microspheres[J].J Pharm sci,1998,87(2):246.
10Goodwin SC,Bittner CA,Peterson CL,et al.Single dose Toxicity Study of Hepatic Intra-arterial Infusion of Doxorubicin Coupled to a Novel Magnetically Targeted Drug Carrier[J].Toxicol Sci,2001,60(1):177.
6Eugenio P. Breast cancer in developing countries[J]. Best Practice &Research Clinical Obstetrics & Gynaecology,2012,26 (2): 283 -290.
7Mellor JD,Cassumbhoy M, Jefford M. Clinical guidance on the peri-operative use of targeted agents in solid tumoroncology [ J ]. AsiaPac J Clin Oncol,2011,7(2) :106-113.
8Walker RA, Day SJ. Transferrin receptor expression in nonmalig-nant and malignant human breast tissue [ J ]. J Pathol, 1986,148(3):217 -224.
9Daniels TR,Delgado T. The transferrin receptor part II:targeted de-livery of therapeutic agents into cancer cells [ J]. Clin Immunol,2006,121(2):159 -176.
10Daniels TR,Delgado T,Rpdrigues JA,et al. The transferrin receptorpart 1 : Biology and targeting with cytotjoxic antibodies for the treat-ment of cancer[ J]. Clin Dev Immunol,2006 ,121 (2) : 144 - 158.
